A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker

Journal of Hypertension

Volumn 28, Issue 10, 2010, Pages 2156-2160

  Konoshita, Tadashi ^a   Makino, Yasukazu ^a   Kimura, Tomoko ^a   Fujii, Miki ^a   Wakahara, Shigeyuki ^a   Arakawa, Kenichiro ^a   Inoki, Isao ^a   Nakamura, Hiroyuki ^a   Miyamori, Isamu ^a  

^a University of Fukui   (Japan)

Author keywords

calcium channel blocker; cilnidiipine; L type calcium channel; Ntype calcium channel; reninangiotensin system; rennin

Indexed keywords

ALDOSTERONE; AMLODIPINE BESYLATE; ANGIOTENSIN I; ANGIOTENSIN II; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; RENIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 77957281444     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833d01dd     Document Type: Article

References (29)

1. Corvol P, Soubrier F, Jeunemaitre X. Molecular genetics of the renin -angiotensin-aldosterone system in human hypertension. Pathol Biol (Paris) 1997; 45:229-239.
2. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23:S9-S17.
3. Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, et al. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 2007; 148:2453-2457.
4. Konoshita T, Wakahara S, Mizuno S, Motomura M, Aoyama C, Makino Y, et al. Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 2006; 29:848-852.
5. Konoshita T, Germain S, Philippe J, Corvol P, Pinet F. Evidence that renal and chorionic tissues contain similar nuclear binding proteins that recognize the human renin promoter. Kidney Int 1996; 50:1515-1524.
6. Konoshita T, Makino Y, Wakahara S, Ido K, Yoshida M, Kawai Y, et al. Candidate cis-elements for human renin gene expression in the promoter region. J Cell Biochem 2004; 93:327-336.
7. Konoshita T, Fuchs S, Makino Y, Wakahara S, Miyamori I. A proximal direct repeat motif characterized as a negative regulatory element in the human renin gene. J Cell Biochem 2007; 102:1043-1050.
8. Takahara A. Cilnidipine: a new generation ca channel blockerwith inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009; 27:124-139.
9. Taylor SH, Chen MF, Lee SJK, Koanantakul B, Zhu JR, Santoso T, et al. Efficacy and tolerability of amlodipine in the general practice treatment of essential hypertension in an Asian multinational population. Clin Drug Investig 1998; 16:177-185.
10. Kishi T, Hirooka Y, Konno S, Sunagawa K. Cilnidipine inhibits the sympathetic nerve activity and improves barorefiex sensitivity in patients with hypertension. Clin Exp Hypertens 2009; 31:241-249.
11. Morimoto S, Yano Y, Maki K, Iwasaka T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens 2007; 25:2178-2183.
12. Fuchs S, Philippe J, Corvol P, Pinet F. Implication of Ref-1 in the repression of renin gene transcription by intracellular calcium. J Hypertens 2003; 21:327335.
13. Germain S, Konoshita T, Philippe J, Corvol P, Pinet F. Transcriptional induction of the human renin gene by cyclic AMP requires cyclic AMP response element-binding protein (CREB) and a factor binding a pituitary-specific trans-acting factor (Pit-1) motif. Biochem J 1996; 316:107-113.
14. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 2000; 16:521-555.
15. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, et al. Nomenclature of voltage-gated calcium channels. Neuron 2000; 25:533-535.
16. Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ, et al. Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 1988; 239:57-61.
17. Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. BrJ Pharmacol 1997; 122:37-42.
18. Takahara A, Dohmoto H, Hisa H, Satoh S, Yoshimoto R. Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs. Jpn J Pharmacol 1997; 75:27-32.
19. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101:1-13.
20. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, et al. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol 2009; 30:155-161.
21. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51:742-748.
22. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266.
23. SarnakMJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169. (Pubitemid 37337595)
24. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63:2254-2261.
25. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927.
26. Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006; 70:151-156.
27. Fujisawa T, Ikegami H, Noso S, Hiromine Y, Kawabata Y, Nishino M, et al. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy. J Diabet Complic 2007; 21:252-257.
28. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72:1543-1549.
29. Konoshita T, Kato N, Fuchs S, Mizuno S, Aoyama C, Motomura M, et al. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care 2009; 32:1485-1490.